Press Release
SoftBank Focuses On The Layout Of The Metaverse With AOS To Create A Brand-New Future
Recently, Softbank Ventures Asia publicly announced that it has begun to focus on Metaverse and invested in the AOS project. It will cooperate with AOS to connect and integrate more Metaverses in AI, NFT, robotics, and other fields, and carry the development of large-scale killer applications.
The enthusiastic investment in Metaverse has not subsided, but it has risen again. The technology giants have all entered the Metaverse. Facebook plans to fully transform into Metaverse before 2025, and will set up a product team to accelerate investment in VR/AR and the creator community; Bytedance, which has always believed in Striving for Miracles, merged Mutong Technology for 4 billion USD, and begin to lay out the Metaverse; Axie Infinity builds NFT games based on the Metaverse, subverting the traditional game mode and becoming a phenomenon-level game product; miHOYO, the developer of “Genshin Impact”, formed an AI scientist inverse entropy team, and self-developed Avatar Luming to explore the brain-computer interface. Through investment, miHOYO has successfully deployed the social Metaverse Soul; the Internet industry is renewing and iterating rapidly, and companies need to attach importance to meet unknown concepts and challenges or be left behind by the times.
In the Metaverse era, everything has virtual avatars. The concept of Metaverse seems to be still in the mist today, but the prelude to the new era has been opened, and it is closer than you think.
The popularization of the term Metaverse was cited from the novel Avalanche by American science fiction writer Neil Stephenson in 1992. In his book, he used the word Metaverse for the first time without foundation and described it as a parallel universe projected from the real world through technical means such as the Internet. However, anyone who has watched the movie “Ready Player One” by the great director Steven Spielberg should probably understand this concept. Like the “Oasis” in the movie, the company has created a realistic virtual world outside of the real world. Every player in the real world has another identity in the virtual world, establishes another social circle, and leads another life. Although the Metaverse is only a virtual world, its immersion is so vivid that you will think it is the real world and enjoy life in this new world.
AOS (Artificial Intelligence Operating System) is the first operating system developed by Canada Unicorn Park, based on the underlying blockchain technology to connect the Metaverse. By building a Metaverse bridge online, and using robots as an intelligent carrier offline to build an ecosystem between Metaverses and provide a new experience for integration with Metaverse and the real world.
Based on AOS, users could create an AI NFT that has autonomous consciousness and advanced self-learning capability; And it also gets influenced by the distributed personality database on the chain to build character, and gradually complete neural network-style self-learning and improvements. Most of all, the distributed character database is based on the “Book of Changes” and appropriately constructs the character of AI; users can inject their favorite characters, personalities, voices, etc., into their own AI NFT, and tame it to learn more skills. AOS encourages users to integrate more characters and personalities, combined with NFT to create different artistic values. The custom AI itself has NFT attributes. Users can customize the appearance of AI on the network, and can also authorize access to a third-party character customization system, such as specific character images and voices, and third-party NFT star voices and appearances, packaged in the form of NFT used for trading and collection.
AOS connects the first-generation physical carrier, the AI four-wheel driving robot Mars_1 with the Metaverse and the real world, creating a new user experience.
Mars_1 is a highly integrated artificial intelligence robot product. Its appearance is in the form of a four-legged driving robot dog. It adopts an original five-layer motion control technology and several technical indicators are in a leading position in the global industry. Mars_1 has integrated the Internet of Things, 5G, virtual reality/augmented reality, intelligent driving, swarm intelligence, and other technologies. Mars_1 will obey commands and gradually be closer to a dog and then become to a good assistant to humankind.
On the road to the Metaverse, AOS always hopes to leave a strong and colorful stroke in its own way. Connect the Metaverse through AI and map out the experience and lifestyle of the future. For the world that people dream of, high-intelligence AI coupled with linkage with robots will be an indispensable component of this era. As the aboriginal and basic units of the Metaverse, these virtual species based on AOS will continue to establish connections with us beyond human beings in the infinite space and time of the future, transcending the fetters of races.
Sun Zhengyi believes: “We are about to experience the biggest change in human history. AI will eventually replace human beings. This is not only reflected in knowledge but also in intelligence. This change will happen in this century, and then in the next 30 years, there is no doubt that our focus is on AI, intelligent robots, and the IOTs.” Based on this analysis and judgment, SoftBank has frequently carried out large-scale layouts in the fields of AI, intelligent robots, and IOTs. Start from all aspects to create a powerful robot empire. Today, SoftBank’s industries have completed the layout of the future of the new Internet field as Sun Zhengyi said in the past, and completed more than half of the investment of unicorn companies on a global scale, laying a foundation for the subsequent development of the IOTs in the world.
As a world-renowned “Animation Kingdom”, Japan has an irreplaceable influence in the global animation field. After half a century of development, the Japanese animation industry has formed an extremely large system, making Japan the world’s largest animation production and exporting country, and it also around animation IP to derive cultural and creative products, such as GK. With the development of smart technology, they also work hard in the direction of intelligence for GK. Headquartered in Japan, SoftBank has a unique geographical location and is deeply immersed in Japanese IP culture. This collaboration with AOS will further promote the combination of the GK industry and the AIindustry, and provide AOS with a steady stream of IP resources. Users’ favorite characters such as Luffy, Conan, Sailor Moon, Sakuragi Hanamichi, Inuyasha, etc., can inject their image and personality into AI to create your smart figure. Each AI figure is a unique individual, and different parameters also create different expressions and styles. At the same time, when users have more exchanges with AI, they will gradually become familiar with the user’s temper and preferences and adjust their apparent personality in real-time and dynamically making it infinitely close to the form that we want to see eventually.
The product made by a single company is not enough to be called a Metaverse but constitutes an ecological system. With the deep participation of users, if it is successful in collective efforts to build a more interoperable system, and it can be transformed into different layers, then it should be called a Metaverse. AOS is committed to becoming the link between the physical world and the virtual world, as a bridge between various Metaverses to connect the Metaverse and continue to build a new Metaverse ecology. This will be the top priority in the next stage of the development of the Internet after the mobile Internet.
What kind of world will mankind be in the future? SoftBank Asia and AOS have worked together because of the same concept for Metaverse and jointly created such a grand concept, standing at the forefront of the Metaverse economic tide, seizing opportunities, embracing the new future, and believing that with their win-win cooperation, they will give a perfect answer for the world.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
Boca Raton, Florida, October 21st, 2026, FinanceWire
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel
, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.
The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel for individual eligible patients before local marketing approval or broad commercial availability.
The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel’s international commercial footprint and scale as additional markets become available.
“This agreement marks an important step in moving Ebstrocel
“We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”
About Ebstrocel
Ebstrocel (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.
About Uniphar Plc.
Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.
Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.
Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.
From molecule to market and beyond.
For more information, please visit www.uniphar.com
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.
INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:
- CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
- XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.
To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.
Forward Looking Statements
The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom (EbstrocelTM, pobistrocel), XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
Daniel Carlson
Head of Investor Relations
(415) 509-4590
Uniphar Contacts:
Media Contacts:
Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com
Contact
Uniphar
NPS_Ebstrocel@uniphar.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Warnickshire, UK, October 21st, 2026, FinanceWire
Data Accounting Highlights Its Approach to Financial Investigations and Announces International Expansion and AI Assistant Launch
Supporting financial transparency through forensic accounting, cross-border financial analysis, and assistance for individuals affected by financial losses.
Data Accounting continues to develop its capabilities in financial analysis, forensic accounting, and international compliance, helping businesses and individuals navigate complex financial situations.
As part of its international development strategy, Data Accounting is preparing to expand its presence across the United Arab Emirates, Australia and Singapore in late 2026 and early 2027. The planned expansion reflects the firm’s intention to broaden its international reach and support individuals and businesses dealing with complex financial matters across different jurisdictions.
Alongside this expansion, Data Accounting is developing a new AI-powered assistant, scheduled for launch in the first quarter of 2027. The assistant is intended to help individuals who have suffered financial losses, including those arising from potentially unsuitable financial advice or unclear regulatory processes, identify the nature of their concerns, organize relevant information and prepare their cases for review by Data Accounting’s team. The initiative aims to make the initial assessment process more accessible and help individuals understand what information may be relevant to their circumstances.
As financial transactions become increasingly international, the need for accurate documentation, reliable financial records, and effective oversight continues to grow. Data Accounting focuses on examining financial information, reviewing transaction histories, and identifying inconsistencies that may require further investigation or clarification.
Its work encompasses the analysis of financial statements, accounting documentation, tax-related records, and cross-border fund movements. Through structured review procedures and analytical techniques, the firm aims to help identify discrepancies, improve financial transparency, and support informed decision-making.
Forensic accounting can play an important role in understanding unusual transaction patterns, assessing the completeness of financial records, and identifying potential weaknesses in accounting or compliance procedures. Where concerns arise, a systematic examination of the available evidence can help clarify the circumstances and determine whether further professional or legal review may be appropriate.
Financial Support for Businesses and Individuals
Financial difficulties can affect both businesses and private individuals. In particular, individuals who have suffered financial losses may face uncertainty when trying to understand what happened, establish the status of their funds, or determine what options may be available to them.
Data Accounting aims to assist individuals affected by financial losses by helping them review relevant financial documentation, organize transaction records, and examine the circumstances surrounding their cases. This includes cases in which individuals have concerns about financial advice they received or difficulties understanding regulatory processes. Depending on the situation, this work may help identify discrepancies, clarify the movement of funds, and establish a clearer picture of the available evidence.
The planned AI assistant will provide an additional starting point for individuals seeking to explain their circumstances and organize information for assessment by the firm’s team. Each case will require an individual review, and potential next steps will depend on the circumstances, the documentation available, and the relevant legal and regulatory framework. Where appropriate, individuals may need to seek independent legal advice or contact the relevant financial institution or competent authority.
For businesses, sound financial oversight remains equally important. Companies operating across borders often manage international suppliers, overseas payments, multi-country payroll arrangements, and complex tax obligations. Weak documentation or inadequate internal controls can create financial uncertainty, operational difficulties, and compliance risks.
Data Accounting supports businesses seeking assistance with international accounting, tax advisory, financial reviews, and administrative processes. Its approach emphasizes accurate record-keeping, structured analysis, and the identification of potential weaknesses that may benefit from further attention.
Supporting Transparency Through Financial Analysis
Financial investigations require attention to detail, a methodical approach to evidence, and a clear understanding of accounting principles and applicable compliance requirements.
Data Accounting’s services focus on helping clients assess financial information, examine unusual transaction patterns, and obtain greater clarity regarding accounting and administrative matters. Depending on the circumstances and the scope of an engagement, this work may support internal reviews, financial assessments, or further independent professional examination.
By helping clients organize documentation and understand complex financial information, the firm seeks to support more informed decisions and improved financial accountability.
The planned international expansion and AI assistant launch represent further steps in Data Accounting’s development, combining its existing financial analysis capabilities with new ways for individuals and businesses to engage with the firm.
About Data Accounting
Data Accounting provides financial and accounting-related services for businesses and individuals seeking greater clarity and transparency in financial matters. Its areas of focus include international accounting, tax advisory, financial analysis, administrative support, and forensic accounting-related reviews.
The firm aims to help clients understand complex financial information, improve documentation practices, examine financial discrepancies, and identify opportunities to strengthen accounting and compliance procedures.
For more information about Data Accounting and its services, visit https://data-accounting.com/.
Contact
Jackie Cox
Data Accounting
reception@mail-data-accounting.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Saudi Arabia, 21st Oct 2026, Grand Newswire – Saudi digital content creator Nawaf Alzahrani has officially launched his personal blog, marking a new step in his digital media presence and providing a dedicated platform for sharing updates, exclusive releases, and project announcements.
The new blog aims to strengthen Alzahrani’s online presence by offering readers a central destination for following his work, exploring project developments, and accessing new digital content.
A New Platform for Exclusive Content
Alzahrani’s official blog is designed to serve as an editorial platform for project coverage, specialized insights, and direct updates. The initiative creates an additional channel through which audiences can stay informed about his activities and upcoming releases.
By launching a dedicated blog, Alzahrani is expanding his digital publishing presence and establishing a platform to support his long-term development goals.
A Vision for Future Growth
Commenting on the launch, Alzahrani emphasized his ambitions for the future and the role of the new platform in supporting his broader vision.
“Launching this platform provides a structured environment to support our future growth and deliver higher-value content to our community,” Alzahrani stated.
The blog reflects his commitment to developing new ways to share content, communicate updates, and build stronger connections with his audience.
Upcoming Releases and Updates
The official blog is now live and open to the public. A series of digital releases and special updates is scheduled for publication in the coming period.
Readers can visit the platform to follow future announcements and discover updates about Alzahrani’s projects as new content becomes available.
About Nawaf Alzahrani
Nawaf Alzahrani is a Saudi digital content creator. Channel owner H2rfez fM and a blog News Shop His newly launched personal blog provides a dedicated online platform for project updates, digital releases, specialized insights, and announcements about his work.
Media Contact
Organization: H2rfez fM
Contact
Person: Nawaf Alzahrani
Website:
https://smarline.ne
Email:
H2rfez1@gmail.com
Country:Saudi Arabia
The post Saudi Content Creator Nawaf Alzahrani Launches Official Blog
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Saudi Content Creator Nawaf Alzahrani Launches Official Blog
Data Accounting Selected in 2026 to Conduct Financial Audits in EU
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release5 days ago
Midwest Ragdolls Highlights Why a Kitten’s Early Environment Matters
-
Press Release7 days ago
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro
-
Press Release4 days ago
From Karmayogi to the World Stage: Dr. Hemant Garg Wins “Excellence in AI for Public Policy”, Charts India’s Path to the AI Big League
-
Press Release6 days ago
Exhibit at CES 2027: Showcasing GENCHI, the Immersive Avatar Service Called Crazy by a U.S. Angel Investor
-
Press Release1 week ago
Kira AI Launches AI Workspace that Thinks and Acts Across Everything Users Do, Say, and Decide
-
Press Release1 week ago
Evolution Metals & Technologies Corp. Reaffirms $400 Million to $460 Million FY2027 Revenue Guidance, Unveils Eight Sintered Magnet Grades Covering an Estimated 75% of Global NdFeB Revenue, and Moves to Answer U.S. Army Call for Rare Earth Magnets
-
Press Release4 days ago
U-topia Launches Public Beta as Global Builders Gather for U-Hackathon
-
Press Release4 days ago
Karviva and Founder Dr. Angela Zeng Featured in 2026 USA TODAY Food as Medicine Edition.